These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
610 related articles for article (PubMed ID: 29026946)
1. PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival. Rahbar K; Boegemann M; Yordanova A; Eveslage M; Schäfers M; Essler M; Ahmadzadehfar H Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):12-19. PubMed ID: 29026946 [TBL] [Abstract][Full Text] [Related]
2. Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving Kessel K; Seifert R; Weckesser M; Roll W; Humberg V; Schlack K; Bögemann M; Bernemann C; Rahbar K Theranostics; 2020; 10(17):7645-7655. PubMed ID: 32685010 [No Abstract] [Full Text] [Related]
3. The value of tumor markers in men with metastatic prostate cancer undergoing [ Yordanova A; Linden P; Hauser S; Feldmann G; Brossart P; Fimmers R; Essler M; Holdenrieder S; Ahmadzadehfar H Prostate; 2020 Jan; 80(1):17-27. PubMed ID: 31579967 [TBL] [Abstract][Full Text] [Related]
4. Second line chemotherapy and visceral metastases are associated with poor survival in patients with mCRPC receiving Kessel K; Seifert R; Schäfers M; Weckesser M; Schlack K; Boegemann M; Rahbar K Theranostics; 2019; 9(17):4841-4848. PubMed ID: 31410185 [TBL] [Abstract][Full Text] [Related]
5. Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with Heck MM; Tauber R; Schwaiger S; Retz M; D'Alessandria C; Maurer T; Gafita A; Wester HJ; Gschwend JE; Weber WA; Schwaiger M; Knorr K; Eiber M Eur Urol; 2019 Jun; 75(6):920-926. PubMed ID: 30473431 [TBL] [Abstract][Full Text] [Related]
6. Influence of short-term dexamethasone on the efficacy of Derlin T; Sommerlath Sohns JM; Schmuck S; Henkenberens C; von Klot CAJ; Ross TL; Bengel FM Prostate; 2020 May; 80(8):619-631. PubMed ID: 32187729 [TBL] [Abstract][Full Text] [Related]
7. Bräuer A; Grubert LS; Roll W; Schrader AJ; Schäfers M; Bögemann M; Rahbar K Eur J Nucl Med Mol Imaging; 2017 Sep; 44(10):1663-1670. PubMed ID: 28624848 [TBL] [Abstract][Full Text] [Related]
8. Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving Sathekge M; Bruchertseifer F; Vorster M; Lawal IO; Knoesen O; Mahapane J; Davis C; Reyneke F; Maes A; Kratochwil C; Lengana T; Giesel FL; Van de Wiele C; Morgenstern A J Nucl Med; 2020 Jan; 61(1):62-69. PubMed ID: 31101746 [TBL] [Abstract][Full Text] [Related]
9. [ Hofman MS; Violet J; Hicks RJ; Ferdinandus J; Thang SP; Akhurst T; Iravani A; Kong G; Ravi Kumar A; Murphy DG; Eu P; Jackson P; Scalzo M; Williams SG; Sandhu S Lancet Oncol; 2018 Jun; 19(6):825-833. PubMed ID: 29752180 [TBL] [Abstract][Full Text] [Related]
11. Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [ Ahmadzadehfar H; Wegen S; Yordanova A; Fimmers R; Kürpig S; Eppard E; Wei X; Schlenkhoff C; Hauser S; Essler M Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1448-1454. PubMed ID: 28488028 [TBL] [Abstract][Full Text] [Related]
12. Delayed response after repeated Rahbar K; Bögeman M; Yordanova A; Eveslage M; Schäfers M; Essler M; Ahmadzadehfar H Eur J Nucl Med Mol Imaging; 2018 Feb; 45(2):243-246. PubMed ID: 29134280 [TBL] [Abstract][Full Text] [Related]
13. Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of Violet J; Sandhu S; Iravani A; Ferdinandus J; Thang SP; Kong G; Kumar AR; Akhurst T; Pattison DA; Beaulieu A; Mooi J; Tran B; Guo C; Kalff V; Murphy DG; Jackson P; Eu P; Scalzo M; Williams S; Hicks RJ; Hofman MS J Nucl Med; 2020 Jun; 61(6):857-865. PubMed ID: 31732676 [No Abstract] [Full Text] [Related]
14. Efficacy and safety of Yadav MP; Ballal S; Sahoo RK; Tripathi M; Seth A; Bal C Theranostics; 2020; 10(20):9364-9377. PubMed ID: 32802197 [No Abstract] [Full Text] [Related]
15. Prediction of response and survival after standardized treatment with 7400 MBq Rasul S; Hartenbach M; Wollenweber T; Kretschmer-Chott E; Grubmüller B; Kramer G; Shariat S; Wadsak W; Mitterhauser M; Pichler V; Vraka C; Hacker M; Haug AR Eur J Nucl Med Mol Imaging; 2021 May; 48(5):1650-1657. PubMed ID: 33128131 [TBL] [Abstract][Full Text] [Related]
16. [ Emmett L; Subramaniam S; Crumbaker M; Nguyen A; Joshua AM; Weickhardt A; Lee ST; Ng S; Francis RJ; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Gedye C; Rutherford NK; Sandhu S; Kumar AR; Pook D; Ramdave S; Nadebaum DP; Voskoboynik M; Redfern AD; Macdonald W; Krieger L; Schembri G; Chua W; Lin P; Horvath L; Bastick P; Butler P; Zhang AY; Yip S; Thomas H; Langford A; Hofman MS; McJannett M; Martin AJ; Stockler MR; Davis ID; Lancet Oncol; 2024 May; 25(5):563-571. PubMed ID: 38621400 [TBL] [Abstract][Full Text] [Related]
17. Response assessment using Grubmüller B; Senn D; Kramer G; Baltzer P; D'Andrea D; Grubmüller KH; Mitterhauser M; Eidherr H; Haug AR; Wadsak W; Pfaff S; Shariat SF; Hacker M; Hartenbach M Eur J Nucl Med Mol Imaging; 2019 May; 46(5):1063-1072. PubMed ID: 30569186 [TBL] [Abstract][Full Text] [Related]
19. Should Lutetium-prostate specific membrane antigen radioligand therapy for metastatic prostate cancer be used earlier in men with lymph node only metastatic prostate cancer? Yaxley WJ; McBean R; Wong D; Grimes D; Vasey P; Frydenberg M; Yaxley JW Investig Clin Urol; 2021 Nov; 62(6):650-657. PubMed ID: 34729965 [TBL] [Abstract][Full Text] [Related]
20. Therapeutic Responses and Survival Effects of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castrate-Resistant Prostate Cancer: A Meta-analysis. Kim YJ; Kim YI Clin Nucl Med; 2018 Oct; 43(10):728-734. PubMed ID: 30059428 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]